Home LiteratureArticle Details
PMID: 3905967 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 135 ·No. 6 ·1985-12-00 ·Pages 4281-8

Piontek GE, Taniguchi K, Ljunggren HG, Grönberg A, Kiessling R, Klein G, Kärre K

Abstract

Two H-2 negative variants of the YAC-1 lymphoma were selected by mutagenization and sequential in vitro selections and compared with wild-type cells for changes in NK sensitivity and H-2 expression after interferon treatment or in vivo passage. The H-2 negative variants and the low H-2 expressor YAC-1 wild-type cells had similar NK sensitivity. However, IFN-beta or recombinant IFN-gamma pretreatments increased the H-2 expression of YAC-1 and protected them from NK lysis, whereas the H-2 variants, which remained H-2 negative, were not protected and often more sensitive to NK lysis. The H-2 variants were similarly susceptible as wild-type cells to three other cellular effects of interferon: protection from virus infection, modulation of Con A capping, and inhibition of cell proliferation. Thus, the only interferon-mediated effect that distinguished the H-2 negative variants from wild-type cells was the inability of the former to increase their H-2 expression and decrease their NK sensitivity. The wild-type YAC-1 line showed increased H-2 expression and decreased NK sensitivity after in vivo passage. In contrast, in vivo passaged H-2 variants showed no reexpression of H-2, and remained NK sensitive. The altered responses to interferon and in vivo passage were specific for loss or down-regulation of H-2, because Thy-1 loss (H-2 positive) YAC-1 variants behaved as the wild-type cells in all respects. This study supports the hypothesis that NK cells may function in vivo to eliminate host cells that fail to express H-2 after interferon stimulation during an immune response; such cells are a potential threat because they may escape recognition by T lymphocytes despite the expression of viral or tumor-associated antigens.

MeSH Terms
Animals Antilymphocyte Serum/pharmacology Cell Line Cytotoxicity, Immunologic/drug effects Genetic Variation H-2 Antigens/genetics,immunology Interferon Type I/pharmacology Killer Cells, Natural/drug effects,immunology,metabolism,transplantation Mice Neoplasm Transplantation T-Lymphocytes, Cytotoxic/immunology beta 2-Microglobulin/metabolism
Chemicals
Antilymphocyte Serum H-2 Antigens Interferon Type I beta 2-Microglobulin
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Piontek G E
Taniguchi K
Ljunggren H G
Grönberg A
Kiessling R
Klein G
Kärre K
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
1985-12-00
Pages
4281-8
Language
English
Region
United States
NLM ID
2985117R
Subset
IM
Grants
NCI NIH HHS · 2 R01 CA 25250-07 · United States
NCI NIH HHS · 5 R01 CA 26782-05 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]